PTC Therapeutics sells remaining Evrysdi royalty stake to Royalty Pharma for $240M upfront

PTC THERAPEUTICS, INC.

Sold remaining 9.5111%/16.6666% royalty interest in Evrysdi worldwide net sales for $240M upfront cash.
Up to three additional $20M payments contingent on Royalty Pharma receiving >$347M (2027), $363M (2028), $379M (2029) in royalty payments.
After closing, Royalty Pharma owns 100% of the Evrysdi royalty; PTC retains no interest.
Transaction effective December 29, 2025, under Amendment No. 2 to existing royalty purchase agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PTC THERAPEUTICS, INC. amended Amendment No. 2 to Amended and Restated Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at $240.0 million in upfront cash consideration (effective 2025-12-29).

Action: amendment
Counterparty: Royalty Pharma Investments 2019 ICAV
Value: $240.0 million in upfront cash consideration
Effective: 2025-12-29

Exact text from the filing

On December 29, 2025, PTC Therapeutics, Inc. (the “Company”), Royalty Pharma Investments 2019 ICAV (“RPI”), and, for the limited purposes set forth in the Purchase Agreement (as defined below), Royalty Pharma plc, entered into an Amendment No. 2 to Amended and Restated Royalty Purchase Agreement (the “Amendment”), which amends that certain Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023, as amended by Amendment No. 1 dated June 17, 2024 (the “Purchase Agreement”).

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-124837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.